Kevin Feeley Sells 12,019 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 12,019 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44. Following the completion of the transaction, the chief financial officer now owns 32,932 shares in the company, valued at approximately $2,429,064.32. This represents a 26.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total value of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The shares were sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Trading Up 0.1 %

Shares of NASDAQ:WGS opened at $80.52 on Wednesday. GeneDx Holdings Corp. has a 52 week low of $1.41 and a 52 week high of $89.11. The company’s 50 day moving average is $60.46 and its two-hundred day moving average is $40.26. The company has a market cap of $2.21 billion, a PE ratio of -25.89 and a beta of 2.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx’s quarterly revenue was up 44.3% on a year-over-year basis. During the same period last year, the firm earned ($0.82) earnings per share. Equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. TD Cowen upped their target price on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BTIG Research raised their price target on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Craig Hallum upped their price objective on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their target price on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $59.33.

Institutional Investors Weigh In On GeneDx

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in GeneDx in the second quarter valued at $34,000. nVerses Capital LLC acquired a new stake in shares of GeneDx during the second quarter worth about $50,000. CWM LLC purchased a new stake in shares of GeneDx in the 3rd quarter valued at about $89,000. Verition Fund Management LLC boosted its position in shares of GeneDx by 12.9% in the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock valued at $1,097,000 after purchasing an additional 2,945 shares during the period. Finally, American Century Companies Inc. grew its stake in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after buying an additional 4,573 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.